RxDoctor Payments Data

Ann Becker, MD

Urology · Raleigh, NCNPI 1588688642

Payments from drug & device makers

$4,340in general payments, 2019–2025

Across 107 payments — averaging $40.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$2K
  • Astellas Pharma US Inc$462
  • Sumitomo Pharma America, Inc.$294
  • Johnson & Johnson$248
  • AbbVie$241
  • Medtronic$197
  • plus $1K from 19 others

What the payments were for

  • Travel & lodging$1,24329%
  • Food & beverage$2,92967%
  • Education$1674%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,340 in reported general payments places this provider in the 60th percentile of 434 urology providers in North Carolina.

See all urology providers in North Carolina

Medicare billing

Part B allowed, 2024
$121,372
Medicare patients
369
Services billed
2,649

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron104$90,309
GemtesaVibegron78$68,273
Methenamine Hippurate69$5,057
Estradiol76$4,842
Tamsulosin Hcl308$4,592
Finasteride148$2,236
Trospium Chloride35$1,980
Trospium Chloride ErTrospium Chloride12$1,237
Testosterone Cypionate26$1,189
Tadalafil19$1,167
Fesoterodine Fumarate ErFesoterodine Fumarate17$718
Cefdinir48$519
NitrofurantoinNitrofurantoin Macrocrystal16$405
Oxybutynin Chloride ErOxybutynin Chloride14$404
Amitriptyline Hcl12$381

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$462$90,309104 claims
Sumitomo Pharma America, Inc.Gemtesa$294$68,27378 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 434 urology providers in North Carolina.

Other urology in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →